Objective The frequency of pulmonary nontuberculous mycobacteriosis (pNTM), chronic lower respiratory tract infections (cLRTIs), and pneumonia in patients with allergic bronchopulmonary mycosis (ABPM) without cystic fibrosis has not yet been fully investigated. Methods We retrospectively analyzed 42 patients with ABPM focusing on the frequency of pNTM and cLRTIs, acute exacerbation of cLRTIs, and pneumonia. Results During a median follow-up period of 2,299 days (range, 118-6,138 days), 7 patients developed pNTM (mainly Mycobacterium avium complex), and 21 patients developed cLRTI (mostly from Staphylococcus aureus followed by Pseudomonas aeruginosa). Twelve patients developed 21 episodes of acute exacerbation of cLRTIs, and 4 patients developed pneumonia. Conclusion Patients with ABPM can have concomitant NTM infection and, not uncommonly, cLRTI, and they can also sometimes develop pneumonia or an acute exacerbation of cLRTI.
Introduction
Allergic bronchopulmonary mycosis (ABPM) is a clinical syndrome occurring predominantly in patients with asthma or cystic fibrosis (CF). Several host characteristics have been identified to explain the development of ABPM (1) , which underline the importance of an impaired airway clearance and hypersensitivity to fungi.
In contrast, nontuberculous mycobacteria (NTM), which are widely distributed in the environment with high isolation rates worldwide, have been increasing and have become a concern in clinical practice. Because patients with ABPM characteristically have underlying impaired clearance and bronchiectasis, we hypothesized that patients with ABPM are susceptible to pulmonary nontuberculous mycobacteriosis (pNTM) and chronic lower respiratory tract infections (cLRTIs). However, to our knowledge, there has only been one report (2) investigating the prevalence of pNTM and chronic bacterial infection in the lower airways; therefore, we investigated the prevalence of these conditions in patients with ABPM.
Materials and Methods
We retrospectively analyzed data of patients with ABPM diagnosed from 1993 through 2014. Diagnosis of ABPM was established when patients either met ! 6 of the primary criteria of Rosenberg and Patterson (3) or the pathological findings (mucoid impaction of the bronchi containing allergic mucin and fungal hyphae) were satisfied (4, 5) . The duration of the follow-up period was from the diagnosis of ABPM, regardless of the clinical or pathological diagnosis, to the final presentation. Diagnosis of pNTM was made when clinical criteria, which require pulmonary symptoms, radiological findings (nodular or cavitary opacities), and isolation of NTM from at least one respiratory sample, were met (6). Diagnosis of cLRTI was made when chronic respiratory symptoms suggestive of lower airway tract infections and repeated isolation of bacteria were found. Pneumonia and acute exacerbation of cLRTIs were diagnosed on the basis of symptoms suggestive of acute lower respiratory tract infections that require antibiotics, with or without the development of infiltration on chest X-ray. This study was approved by the institutional review board of Saitama Cardiovascular and Respiratory Center.
Results
From 1993 through 2014, 42 patients were diagnosed as having ABPM without CF. All patients underwent bronchoscopy. Diagnosis of ABPM was made based on clinical criteria in 20 and by pathological findings in 26 patients (the sum of the diagnostic basis exceeded 42 because some patients met both clinical and pathological criteria). Histologic samples were obtained via bronchoscopy in 24 and operation in 2 patients. Patient characteristics are listed in Table 1. Patients were 57.1±15.0 years old and 14 were men. Fifteen patients had a smoking history, 25 (59.5%) had bronchial asthma, and 41 of the 42 (97.6%) patients had central bronchiectasis. The etiology of ABPM was identified in 35 patients (Aspergillus sp. in 25, Schizophyllum commune in 6, Penicillium sp. in 3, and Candida sp. in 1). ABPM patients received systemic (n=27) or inhaled (n=26) corticosteroid therapy or itraconazole (n=22). The median follow-up period was 2,299 days (range, 118-6,138 days) after the diagnosis of ABPM. Ten patients were dropped from follow-up before 2014 because they were referred to local physicians, and no patients died during follow-up.
Among the 42 patients with ABPM, NTM was isolated in 8 patients, which included 7 patients with pNTM and 1 patient with NTM colonization (Table 2) . One patient who was reported previously was included (7) . In that patient, isolated NTM were regarded as colonization in 2009; however, the patient developed pNTM (Mycobacterium avium complex) in 2014. Etiology of pNTM included M. avium complex in 4, M. avium complex + M. abscessus in 1, M. fortuitum + M. avium complex + M. kansasii in 1, and M. avium complex + M. simiae + M. gordonae in 1. In one patient with NTM colonization, the NTM were not identifiable. The cumulative incidence rate is shown in Figure. The median duration from the diagnosis of ABPM to the development of pNTM was 1,682 days (range, 331-4,452 days). Among the patients with ABPM who developed pNTM during the follow-up, 6 of 7 (85.7%) had already received systemic corticosteroid therapy. However, 20 of the 35 (57.1%) patients with ABPM who did not develop pNTM during follow-up had also received systemic corticosteroid therapy.
In contrast, cLRTIs were found in 21 (50.0%) patients, which included Pseudomonas aeruginosa in 8 (19.0%), methicillin-sensitive Staphylococcus aureus in 15 (35.7%), Escherichia coli in 3 (7.1%), Acinetobacter sp. in 4 (9.5%), Streptococcus pneumoniae in 2 (4.8%), Serratia marescens in 2 (4.8%), Haemophilus influenzae in 2 (4.8%), Enterococcus cloacae in 2 (4.8%), Klebsiella pneumoniae in 2 (4.8%), and Moraxella catarrhalis in 1 (2.4%). Among these 21 patients with cLRTIs, 15 (71.4%) had received systemic corticosteroid therapy, whereas 12 (57.1%) of the 21 patients who did not have cLRTIs also received systemic corticosteroids. During the follow-up period, 12 (28.6%) patients developed 21 episodes of an acute exacerbation of cLRTIs, and 4 (9.5%) patients developed pneumonia. The median duration from the diagnosis of ABPM to the development of the initial episode of an acute exacerbation of cLRTI or pneumonia was 1,090 days (range, 88-4,020 days).
Discussion
pNTM was found in 7 (16.7%) of 42 patients with ABPM, most of which included M. avium complex and was consistent with the etiology of NTM in Japan (8) . In contrast, cLRTIs were found in 21 (50.0%) of the 42 patients.
pNTM or NTM colonization can occur in persons with impaired pulmonary clearance mechanisms due to chronic lung diseases (9-11). To date, some patients with allergic bronchopulmonary aspergillosis (ABPA) in whom NTM was isolated have been reported (2, (12) (13) (14) . There have been limited reports regarding the prevalence of pNTM in ABPM (2, 11, 15) . In ABPM patients with CF, 5 of 6 (2) and 3 of 6 (11) patients with ABPM developed pNTM. In patients with ABPM but without CF, 4 of 7 patients developed pNTM (15) . These reports suggest that the frequency of pNTM in ABPM is not low.
Isolation of NTM can indicate the presence of both infection and simple colonization. Most previous reports differentiated pNTM from simple colonization (2, 11) according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria (6), but in some reports (9, 10), pNTM was differentiated from colonization based on histologic findings. In any case, NTM can colonize or infect damaged bronchi such as those seen in advanced ABPM.
Furthermore, there are concerns that the administration of a systemic corticosteroid targeting ABPM can worsen or cause an NTM infection. Previous reports by Mussaffi et al. (2), Levy et al. (11) , and Kunst et al. (15) , and our results suggest that systemic corticosteroid therapy may be responsible for pNTM. Previously, we reported one patient in whom NTM was repeatedly isolated, and the histologic samples obtained via right middle lobe resection showed findings of ABPM (7) . Because pulmonary shadows suggestive of pNTM had not developed and NTM had not been isolated for several years, the presence of NTM was regarded as colonization. The patient received systemic corticosteroid therapy; however, the patient developed pNTM (M. avium complex) 5 years after surgery, which would indicate that when patients with ABPM are regarded as having NTM colonization, careful follow-up is required for the development of NTM infection.
We also investigated the frequency of cLRTIs, acute exacerbations of cLRTIs, and pneumonia in ABPM patients. One half of the ABPM patients showed cLRTIs in the lower airways, and 4 (28.6%) developed pneumonia and 12 (9.5%) developed 21 episodes of acute exacerbation of cLRTIs, which is not uncommon. It is not surprising that cLRTIs occur in patients with CF, which not uncommonly overlaps with ABPM; however, our study did not include any patients with CF. To our knowledge, there have been no reports regarding the frequency of cLRTIs in ABPM patients without CF, but the high frequency of these infections seen, as seen in our results, could have an effect on clinical practice.
There have been no reports on the etiology of cLRTIs in ABPM patients without CF. Isolated organisms found in the cLRTIs in the present study were most frequently methicillin-sensitive Staphylococcus aureus, followed by Pseudomonas aeruginosa, E. coli, and others. Isolation of S. aureus is compatible with a previous report that showed an association between S. aureus and ABPM without CF (16) . P. aeruginosa, E. coli, and H. influenzae were reported to be isolated from patients with bronchiectasis (14, 17) , and there is a report of 3 patients with ABPM accompanied by cLRTIs caused by P. aeruginosa (18) .
Patients with advanced ABPA have bronchiectasis, and ABPA patients commonly receive inhaled or systemic steroid therapy. In addition, underlying impaired airway clearance (1) in ABPM patients is known, which may favor the development of pNTM or cLRTIs. We could not investigate the risk factors for developing pNTM, acute exacerbation of cLRTIs, and pneumonia in ABPM because of the limited number of patients in our study. Our results suggest that ABPM patients are at risk for pNTM and cLRTIs, and these should be investigated in future studies.
The present study has several limitations. First, because this is a nonrandomized observational study, the level of confidence is reduced. Second, the present study was carried out in a single center, and the results may not be applicable to other settings. Third, almost all of the ABPM patients in our study had central bronchiectasis; therefore, our results may not accurately reflect the condition of ABPM patients without central bronchiectasis.
In conclusion, patients with ABPM can have concomitant NTM infection, NTM colonization, and cLRTIs. Pneumonia and an acute exacerbation of cLRTIs are also not uncommon, and careful attention should therefore be paid during the follow-up of patients with ABPM.
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